High density lipoprotein cholesterol / C reactive protein ratio in heart failure with preserved ejection fraction.

Heart failure with preserved ejection fraction High density lipoprotein cholesterol/C reactive protein ratio Inflammation Left ventricular diastolic function Right ventricular systolic function

Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
08 2021
Historique:
revised: 16 02 2021
received: 02 11 2020
accepted: 26 03 2021
pubmed: 3 5 2021
medline: 29 10 2021
entrez: 2 5 2021
Statut: ppublish

Résumé

The impacts of high density lipoprotein cholesterol (HDL-C) as an anti-inflammatory and C reactive protein (CRP) as inflammatory properties on the pathogenesis of heart failure were reported. At present, the clinical significance of the HDL-C/CRP ratio in heart failure with preserved ejection fraction (HFpEF) patients remains unknown. We examined the data on 796 consecutive HFpEF (left ventricular ejection fraction ≥50%) patients hospitalized due to acute decompensated heart failure from the PURSUIT-HFpEF registry, a prospective, multicentre observational study. We calculated the HDL/CRP ratios and evaluated the relationship between the values and clinical outcomes, including degree of cardiac function. The mean follow-up duration was 420 ± 346 days. All-cause death occurred in 118 patients, of which 51 were cardiac deaths. HDL/CRP ≤ 4.05 was independently and significantly associated with all-cause death (odds ratio = 1.84, 95% CI: 1.06-3.20, P = 0.023), and HDL/CRP ≤ 3.14 was associated with cardiac death by multivariate Cox proportional hazard analysis (odds ratio = 2.86, 95% CI: 1.36-6.01, P = 0.003). HDL-C/CRP ratio significantly correlated with the product of the left atrial volume and left ventricular mass index as well as the tricuspid annular plane systolic excursion by multiple regression analysis (standardized beta-coefficient = -0.085, P = 0.034 and standardized beta-coefficient = 0.081, P = 0.044, respectively). HDL-C/CRP ratio was a useful marker for predicting all-cause death and cardiac death and correlated with left ventricular diastolic function and right ventricular systolic function in HFpEF patients.

Identifiants

pubmed: 33934563
doi: 10.1002/ehf2.13350
pmc: PMC8318396
doi:

Substances chimiques

Cholesterol, HDL 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2791-2801

Informations de copyright

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

J Am Coll Cardiol. 2007 Jan 16;49(2):198-207
pubmed: 17222731
Circ Res. 2016 Jan 8;118(1):145-56
pubmed: 26837745
Am J Hypertens. 2003 Nov;16(11 Pt 1):938-44
pubmed: 14573332
Circ Res. 2002 Nov 29;91(11):988-98
pubmed: 12456484
J Card Fail. 2006 Feb;12(1):61-5
pubmed: 16500582
J Am Coll Cardiol. 2010 May 11;55(19):2129-37
pubmed: 20447537
Nat Rev Immunol. 2015 Feb;15(2):104-16
pubmed: 25614320
Circulation. 2008 Apr 1;117(13):1717-31
pubmed: 18378625
Atherosclerosis. 2009 Aug;205(2):522-7
pubmed: 19327776
Am Heart J. 2007 Jul;154(1):172-9
pubmed: 17584573
Circ Res. 2015 Jan 16;116(2):307-11
pubmed: 25593275
Circ J. 2009 Oct;73(10):1893-900
pubmed: 19644216
J Am Coll Cardiol. 2006 Jan 17;47(2):345-53
pubmed: 16412859
J Am Soc Echocardiogr. 2011 Mar;24(3):322-32.e6
pubmed: 21247733
ESC Heart Fail. 2021 Aug;8(4):2791-2801
pubmed: 33934563
Circ Heart Fail. 2016 Apr;9(4):e002729
pubmed: 27072860
Curr Heart Fail Rep. 2017 Aug;14(4):251-265
pubmed: 28667492
Circ J. 2019 Jan 25;83(2):357-367
pubmed: 30416189
Atherosclerosis. 2014 Jan;232(1):1-9
pubmed: 24401210
Eur J Heart Fail. 2008 Jun;10(6):573-80
pubmed: 18457990
Eur J Heart Fail. 2020 Mar;22(3):413-421
pubmed: 31472035
JAMA Intern Med. 2015 Jun;175(6):996-1004
pubmed: 25895156
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Eur Heart J. 2006 Mar;27(6):691-9
pubmed: 15821011
Int J Cardiol. 2000 Nov-Dec;76(2-3):125-33
pubmed: 11104867
PLoS One. 2018 Aug 16;13(8):e0201836
pubmed: 30114262
J Am Heart Assoc. 2020 Jan 7;9(1):e014100
pubmed: 31847660
Am J Cardiol. 2002 Jul 15;90(2):147-9
pubmed: 12106845
Cardiovasc Res. 2014 Aug 1;103(3):341-9
pubmed: 24935434
Lipids Health Dis. 2019 Dec 12;18(1):219
pubmed: 31831002
N Engl J Med. 2006 Jul 20;355(3):260-9
pubmed: 16855266
J Atheroscler Thromb. 2010 May;17(5):436-51
pubmed: 20513953
Handb Exp Pharmacol. 2015;224:181-206
pubmed: 25522988
Sci Rep. 2020 Jan 9;10(1):90
pubmed: 31919384
J Cell Physiol. 2018 Dec;233(12):9237-9246
pubmed: 30076716
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Eur J Heart Fail. 2014 Jul;16(7):758-66
pubmed: 24806206
Med Clin North Am. 2017 Jan;101(1):7-17
pubmed: 27884237
N Engl J Med. 2010 Jan 21;362(3):228-38
pubmed: 20089973
Eur J Heart Fail. 2020 Mar;22(3):391-412
pubmed: 32133741
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71
pubmed: 23684677
Eur Heart J. 2019 Oct 21;40(40):3297-3317
pubmed: 31504452
J Clin Invest. 2011 Jun;121(6):2111-7
pubmed: 21633179
N Engl J Med. 2006 Jul 20;355(3):251-9
pubmed: 16855265

Auteurs

Masamichi Yano (M)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Masami Nishino (M)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Kohei Ukita (K)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Akito Kawamura (A)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Hitoshi Nakamura (H)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Yutaka Matsuhiro (Y)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Koji Yasumoto (K)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Masaki Tsuda (M)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Naotaka Okamoto (N)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Akihiro Tanaka (A)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Yasuharu Matsunaga-Lee (Y)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Yasuyuki Egami (Y)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Ryu Shutta (R)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Jun Tanouchi (J)

Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka, 591-8025, Japan.

Takahisa Yamada (T)

Division of Cardiology, Osaka General Medical Center, Osaka, Japan.

Yoshio Yasumura (Y)

Division of Cardiology, Amagasaki Chuo Hospital, Amagasaki, Japan.

Shunsuke Tamaki (S)

Division of Cardiology, Osaka General Medical Center, Osaka, Japan.

Takaharu Hayashi (T)

Cardiovascular Division, Osaka Police Hospital, Osaka, Japan.

Akito Nakagawa (A)

Division of Cardiology, Amagasaki Chuo Hospital, Amagasaki, Japan.
Department of Medical Informatics, Osaka University Graduate School of Medicine, Suita, Japan.

Yusuke Nakagawa (Y)

Division of Cardiology, Kawanishi City Hospital, Kawanishi, Japan.

Shinichiro Suna (S)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Daisaku Nakatani (D)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Shungo Hikoso (S)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Yasushi Sakata (Y)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH